PPARA and fatty liver disease: Fenofibrate treatment, a peroxisome proliferator-activated receptor α (PPARα) stimulant, not only restored peroxisome deficits and improved mitochondrial function but also reduced hepatic steatosis, demonstrating a critical peroxisome-mitochondrion role in undernutrition-induced fatty liver (9).